Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC11FCD in Newly Diagnosed Glioblastoma
NCT07143812Phase 1Recruiting
- Sponsor
- CHA University
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MSC11FCD in glioblastoma (GBM), sponsored by CHA University. Primary endpoint: Number Of Adverse Events related to the treatment at 12 months. Started Oct 2025; status: recruiting.
02
Drugs
MSC11FCD
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07143812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07143812.